Results Observed News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Results observed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Results Observed Today - Breaking & Trending Today

Most Intensive Ivermectin Use Had 74 Percent Reduction in Excess Deaths in Peru: New Study

Most Intensive Ivermectin Use Had 74 Percent Reduction in Excess Deaths in Peru: New Study
theepochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theepochtimes.com Daily Mail and Mail on Sunday newspapers.

United States , Uttar Pradesh , Francisco Sagasti , Ministry Of Defense , Peruvian Ministry Of Health , World Health Organization , Then Restricted Access , Peruvian Ministry , President Francisco Sagasti , Results Observed ,

AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress

AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress
- In SELECT-PsA 2, 29 percent of bDMARD-IR patients treated with continuous RINVOQ (upadacitinib, 15 mg, once daily) achieved minimal disease activity at 56 weeks, which was consistent with improvements from baseline seen at week 24[1],[2]
- The safety results of RINVOQ 15 mg were consistent with previously reported results in rheumatoid arthritis, with no new significant safety risks identified[1],[3]
- Full results to be presented at the EULAR 2021 Virtual Congress
- RINVOQ is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis[2] ....

Clin Rheumatol , Philip Mease , Mudra Kapoor , Prnewswire Abbvie , Exchange Commission , Joseph Health , European Commission , Abbvie Deutschland Gmbh Co , Virtual Congress , American College Of Rheumatology , Results Observed , Disease Activity , Leeds Enthesitis Index , American College , Rheumatology Research Division , Swedish Medical , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Vie Deutschland Gmbh , Psoriatic Arthritis , Inadequate Response , Week Data , Randomized Controlled Phase , Pract Res Clin , Study Comparing Upadacitinib ,

AbbVie to Present Analysis Evaluating Continuous RINVOQ® Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress

ABBVie today announced results of an analysis from the Phase 3 SELECT-PsA 2 clinical trial, showing that continuous treatment with RINVOQ ® resulted in sustained improvements in disease activity for more than one year among patients with active psoriatic arthritis who have responded inadequately to one or more biologic disease modifying anti-rheumatic drugs . 1 At week 56, 29 percent of patients treated with . ....

Clin Rheumatol , Philip Mease , Mudra Kapoor , Exchange Commission , Joseph Health , European Commission , Abbvie Deutschland Gmbh Co , Virtual Congress , American College Of Rheumatology , Results Observed , Disease Activity , Leeds Enthesitis Index , American College , Rheumatology Research Division , Swedish Medical , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Vie Deutschland Gmbh , Psoriatic Arthritis , Inadequate Response , Week Data , Randomized Controlled Phase , Pract Res Clin , Study Comparing Upadacitinib , Compare Safety ,